Xtl Biopharmaceuticals Ltd Stock Performance
| XTLB Stock | USD 1.10 0.04 3.51% |
The firm maintains a market beta of 0.74, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, XTL Biopharmaceutica's returns are expected to increase less than the market. However, during the bear market, the loss of holding XTL Biopharmaceutica is expected to be smaller as well. At this point, XTL Biopharmaceuticals has a negative expected return of -0.95%. Please make sure to check out XTL Biopharmaceutica's skewness, as well as the relationship between the rate of daily change and period momentum indicator , to decide if XTL Biopharmaceuticals performance from the past will be repeated at some future point.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days XTL Biopharmaceuticals Ltd has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's essential indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:5 | Dividend Date 2017-02-10 | Last Split Date 2017-02-10 |
1 | Acquisition by Edelman Joseph of 32260 shares of XTL Biopharmaceutica at 3.36 subject to Rule 16b-3 | 12/24/2024 |
2 | Acquisition by Edelman Joseph of 94000 shares of XTL Biopharmaceutica at 3.3733 subject to Rule 16b-3 | 01/08/2025 |
3 | Cancer Biopharmaceuticals Market Growth Expected to Achieve 8.01 percent CAGR, Reaching 583.7 Billion USD by 2032 | 01/13/2025 |
4 | Stability Testing of Pharmaceuticals and Biopharmaceuticals - Increase the Likelihood of Studies Receiving Regulatory Approval and Save Resources on Stability T... | 02/06/2025 |
5 | Acquisition by Edelman Joseph of 10050 shares of XTL Biopharmaceutica at 3.1625 subject to Rule 16b-3 | 02/07/2025 |
6 | Day One Biopharmaceuticals Inc Q4 2024 Earnings Report Preview What To Look For | 02/25/2025 |
7 | Day One Biopharmaceuticals, Inc.s Profit Outlook | 02/27/2025 |
8 | Chengdu Easton Biopharmaceuticals Full Year 2024 Earnings EPS CN1.36 | 03/03/2025 |
9 | Day One Biopharmaceuticals, Inc. A Bull Case Theory | 03/05/2025 |
10 | SK Biopharmaceuticals Full Year 2024 Earnings Beats Expectations | 03/13/2025 |
11 | Acquisition by Edelman Joseph of 2040 shares of XTL Biopharmaceutica at 3.23 subject to Rule 16b-3 | 03/14/2025 |
12 | ChromaTan and Landmark Bio Awarded National Institute for Innovation in Manufacturing Biopharmaceuticals Grant to Advance Intensified Recombinant Adeno-Associat... | 03/17/2025 |
13 | Angitia Biopharmaceuticals Presents Data from Phase 12 Study of AGA111 at 2025 AAOS Annual Meeting | 03/18/2025 |
14 | XTLB stock touches 52-week low at 1.13 amid market challenges - Investing.com India | 03/24/2025 |
| Begin Period Cash Flow | 2.1 M |
XTL |
XTL Biopharmaceutica Relative Risk vs. Return Landscape
If you would invest 210.00 in XTL Biopharmaceuticals Ltd on December 26, 2024 and sell it today you would lose (100.00) from holding XTL Biopharmaceuticals Ltd or give up 47.62% of portfolio value over 90 days. XTL Biopharmaceuticals Ltd is currently does not generate positive expected returns and assumes 5.0021% risk (volatility on return distribution) over the 90 days horizon. In different words, 44% of stocks are less volatile than XTL, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
XTL Biopharmaceutica Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for XTL Biopharmaceutica's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as XTL Biopharmaceuticals Ltd, and traders can use it to determine the average amount a XTL Biopharmaceutica's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1896
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | XTLB |
Estimated Market Risk
| 5.0 actual daily | 44 56% of assets are more volatile |
Expected Return
| -0.95 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.19 actual daily | 0 Most of other assets perform better |
Based on monthly moving average XTL Biopharmaceutica is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of XTL Biopharmaceutica by adding XTL Biopharmaceutica to a well-diversified portfolio.
XTL Biopharmaceutica Fundamentals Growth
XTL Stock prices reflect investors' perceptions of the future prospects and financial health of XTL Biopharmaceutica, and XTL Biopharmaceutica fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on XTL Stock performance.
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.16 | ||||
| Operating Margin | (16.61) % | ||||
| Current Valuation | 8.88 M | ||||
| Shares Outstanding | 8.81 M | ||||
| Price To Earning | 4.50 X | ||||
| Price To Book | 1.70 X | ||||
| Price To Sales | 226.86 X | ||||
| Gross Profit | 46 K | ||||
| EBITDA | (764 K) | ||||
| Net Income | (1.78 M) | ||||
| Cash And Equivalents | 5.16 M | ||||
| Cash Per Share | 0.95 X | ||||
| Total Debt | 206 K | ||||
| Current Ratio | 31.26 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (707 K) | ||||
| Earnings Per Share | (0.20) X | ||||
| Market Capitalization | 10.44 M | ||||
| Total Asset | 2.43 M | ||||
| Retained Earnings | (158.25 M) | ||||
| Working Capital | 1.84 M | ||||
| Current Asset | 3 M | ||||
About XTL Biopharmaceutica Performance
By analyzing XTL Biopharmaceutica's fundamental ratios, stakeholders can gain valuable insights into XTL Biopharmaceutica's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if XTL Biopharmaceutica has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if XTL Biopharmaceutica has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 17.2 M | 18.1 M | |
| Return On Capital Employed | (0.40) | (0.38) |
Things to note about XTL Biopharmaceuticals performance evaluation
Checking the ongoing alerts about XTL Biopharmaceutica for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for XTL Biopharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| XTL Biopharmaceutica generated a negative expected return over the last 90 days | |
| XTL Biopharmaceutica has high historical volatility and very poor performance | |
| XTL Biopharmaceutica may become a speculative penny stock | |
| XTL Biopharmaceutica has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (1.78 M) with profit before overhead, payroll, taxes, and interest of 46 K. | |
| XTL Biopharmaceuticals Ltd currently holds about 5.16 M in cash with (707 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.95. | |
| XTL Biopharmaceutica has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: XTLB stock touches 52-week low at 1.13 amid market challenges - Investing.com India |
- Analyzing XTL Biopharmaceutica's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether XTL Biopharmaceutica's stock is overvalued or undervalued compared to its peers.
- Examining XTL Biopharmaceutica's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating XTL Biopharmaceutica's management team can have a significant impact on its success or failure. Reviewing the track record and experience of XTL Biopharmaceutica's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of XTL Biopharmaceutica's stock. These opinions can provide insight into XTL Biopharmaceutica's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for XTL Stock analysis
When running XTL Biopharmaceutica's price analysis, check to measure XTL Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XTL Biopharmaceutica is operating at the current time. Most of XTL Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of XTL Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XTL Biopharmaceutica's price. Additionally, you may evaluate how the addition of XTL Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |